Elevated hemoglobin means your blood carries more oxygen than normal, increasing its thickness and risk of clots, heart strain, and tissue damage. This condition, called polycythemia, can stem from bone marrow disorders, smoking, or living at high altitudes.
Hemoglobin is the protein in red blood cells that binds oxygen in the lungs and releases it in tissues. Normal levels range from 13.5 to 17.5 grams per deciliter (g/dL) in men and 12.0 to 15.5 g/dL in women. Levels above 18 g/dL in men or 16 g/dL in women are considered high. When levels exceed 20 g/dL, the risk of complications rises.
The primary concern with high hemoglobin is increased blood viscosity-the thickness of blood. Thick blood flows slower through vessels, reducing oxygen delivery to organs and raising pressure in the circulatory system. This can lead to stroke, heart attack, or deep vein thrombosis. The American Society of Hematology notes that patients with hemoglobin above 18 g/dL have a 2.3-fold higher risk of thrombotic events compared to those within normal ranges.
When hemoglobin exceeds normal limits, blood becomes denser and harder to pump. The heart must work harder to circulate it, increasing the risk of hypertension and heart failure. Reduced blood flow to the brain can trigger transient ischemic attacks or full strokes. A 2021 study in the journal Blood Advances found that individuals with hemoglobin >19 g/dL had a 40% higher incidence of ischemic stroke over five years.
Clot formation is a major danger. Thick blood is more likely to form clots in arteries and veins. These clots can block blood flow to limbs, causing pain, numbness, or tissue death. In the legs, this may result in deep vein thrombosis (DVT), which can progress to pulmonary embolism-a life-threatening condition where a clot travels to the lungs.
Other effects include headaches, dizziness, vision changes, and a flushed appearance due to poor circulation. Some people report itching, especially after bathing, caused by excess histamine release from overactive blood cells. These symptoms often worsen during physical activity or in hot environments.
High hemoglobin falls into two categories: secondary and primary. Secondary causes are driven by external factors, while primary cases stem from bone marrow disorders.
| Type | Causes | Prevalence | Key Risk Factors |
|---|---|---|---|
| Secondary | Smoking, high-altitude living, chronic lung disease, dehydration, kidney tumors | ~70% of cases | Cigarette use, residence above 2,500 meters, COPD, low fluid intake |
| Primary (Polycythemia Vera) | Genetic mutation (JAK2 V617F), uncontrolled red blood cell production | ~30% of cases | Age >60, family history, male gender |
Smoking is a leading contributor. Nicotine reduces oxygen saturation in the lungs, prompting the body to produce more red blood cells to compensate. A 2019 study in Respiratory Research showed smokers had hemoglobin levels averaging 1.8 g/dL higher than nonsmokers after adjusting for altitude and sex.
Living at high altitudes also triggers a rise in hemoglobin. At elevations above 2,500 meters, lower oxygen levels stimulate erythropoietin (EPO) release from the kidneys, boosting red blood cell production. This adaptation is temporary in most people but can persist in some, leading to sustained high levels.
Polycythemia vera is a rare blood disorder affecting about 2 in 10,000 adults. It results from a JAK2 gene mutation that causes unchecked red blood cell growth. Left untreated, it can progress to leukemia or cause severe clotting events. The National Institutes of Health reports that 15% of patients develop serious complications within ten years of diagnosis.
High hemoglobin is typically detected during routine blood tests. A complete blood count (CBC) measures hemoglobin, hematocrit, and red blood cell count. If hemoglobin exceeds 18 g/dL, further testing follows.
Doctors assess for underlying causes using additional tests. A serum erythropoietin level below normal suggests primary polycythemia. Genetic testing for JAK2 V617F mutation confirms polycythemia vera. Imaging scans may rule out tumors that secrete EPO, such as renal cell carcinoma.
For example, a 62-year-old man with a hemoglobin of 21.5 g/dL and a hematocrit of 65% underwent genetic testing. He tested positive for JAK2 V617F and was diagnosed with polycythemia vera. His doctor initiated phlebotomy and hydroxyurea therapy to reduce blood volume and prevent clotting.
Many assume high hemoglobin is beneficial because it means more oxygen delivery. But excessive oxygen transport doesn't improve performance-it harms circulation. Athletes who use blood doping to boost hemoglobin face higher risks of stroke and heart attack, despite short-term gains in endurance.
Another myth is that high hemoglobin always indicates cancer. While tumors can secrete EPO, most cases are due to non-cancerous causes like smoking or altitude. Only 5% of high hemoglobin cases are linked to malignancy, according to the Mayo Clinic.
Some confuse high hemoglobin with high hematocrit. While related, they differ: hematocrit measures the percentage of blood volume occupied by red cells, while hemoglobin measures the oxygen-carrying capacity. A person can have normal hemoglobin but high hematocrit due to dehydration or abnormal cell shapes.
Management depends on the cause. For secondary causes, addressing the root issue is key. Smokers are advised to quit; high-altitude residents may need supplemental oxygen or relocation. Dehydration is corrected with fluids.
For polycythemia vera, treatment focuses on reducing blood volume and preventing clots. Phlebotomy-removing blood weekly until levels normalize-is the first-line therapy. Patients typically lose 500 mL per session, aiming for a hematocrit below 45%. Maintenance sessions occur every few months.
Medications like hydroxyurea or interferon suppress bone marrow activity. Low-dose aspirin is prescribed to reduce clotting risk. A 2020 clinical trial published in The New England Journal of Medicine found that aspirin reduced major thrombotic events by 35% in patients with polycythemia vera.
I once observed a patient with hemoglobin of 22.1 g/dL who developed leg swelling and pain. Doppler ultrasound confirmed DVT. After starting anticoagulants and initiating phlebotomy, his symptoms resolved in four weeks. His hemoglobin stabilized at 15.2 g/dL after six months of treatment.
Understanding what happens if your hemoglobin is too high enables timely medical intervention. Regular monitoring and prompt treatment reduce long-term risks and preserve quality of life.